ADULT ORAL Updated: May 31, 2022

# Regimen Reference Order - GYNE - olaparib

ARIA: GYNE - [olaparib]

Planned Course: Maintenance after 1<sup>st</sup> line chemotherapy:

Twice daily until disease progression or unacceptable toxicity up to 2 years

(1 cycle = 30 days)

OR

Maintenance after chemotherapy for Relapsed disease:

Twice daily until disease progression or unacceptable toxicity

(1 cycle = 30 days)

Indication for Use: BRCA-Mutated Ovarian Cancer, Maintenance Therapy

### Proceed with treatment if:

ANC equal to or greater than 1.2 x  $10^9/L$  AND Platelets equal to or greater than 75 x  $10^9/L$ 

Contact Physician if parameters not met

## **SEQUENCE OF MEDICATION ADMINISTRATION**

Drug	Dose	CCMB Administration Guideline
olaparib	300 mg	Orally twice daily with or without food
		Swallow whole
		(Self-administered at home)

### **REQUIRED MONITORING**

#### All Cycles

• CBC and biochemistry as per Physician Orders

Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
ondansetron	8 mg	Orally every 8 hours as needed for nausea and vomiting	
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting	

#### INSTRUCTIONS FOR PATIENT

- Instruct patient to continue taking anti-emetic(s) at home
- olaparib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- · Reinforce applicable safe handling precautions of medications, blood and body fluids while on olaparib



ADULT ORAL GYNE - olaparib

#### **ADDITIONAL INFORMATION**

- olaparib can rarely cause pneumonitis
- secondary malignancy (MDS/AML) has been reported with olaparib (rare). Monitor for prolonged cytopenia
- olaparib is teratogenic. Women of childbearing potential should use effective contraception while on olaparib
- olaparib will be dispensed by CCMB Pharmacy

